

# Brian I Rini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3454558/publications.pdf>

Version: 2024-02-01

400  
papers

50,885  
citations

3264

94  
h-index

1919

214  
g-index

409  
all docs

409  
docs citations

409  
times ranked

34791  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	2.6	17
2	A Modern Assessment of Cancer Risk in Adrenal Incidentalomas. <i>Annals of Surgery</i> , 2022, 275, e238-e244.	2.1	34
3	Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 64.e17-64.e24.	0.8	3
4	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	0.9	33
5	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747.	3.2	11
6	Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS404-TPS404.	0.8	0
7	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	3.4	75
8	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 352-352.	0.8	8
9	Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2022, 24, 695-702.	1.8	9
10	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
11	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103
12	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
13	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	3.2	8
14	Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3002-3002.	0.8	6
15	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	0.9	64
16	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e12-e16.	0.9	6
17	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e835-e843.	2.9	103
18	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 167-175.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	3.2	154
20	Severity of illness scores at presentation predict ICU admission and mortality in COVID-19. <i>Journal of Emergency and Critical Care Medicine</i> , 2021, 5, 7-7.	0.7	19
21	Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 341-341.	0.8	0
22	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	0.9	39
23	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	1.7	10
24	Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. <i>Cancer Causes and Control</i> , 2021, 32, 675-680.	0.8	6
25	Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors?. <i>Lancet Oncology</i> , The, 2021, 22, 593-594.	5.1	1
26	Perspectives on under-representation of minority patients (pts) in clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18521-e18521.	0.8	0
27	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. <i>Cell</i> , 2021, 184, 2988-3005.e16.	13.5	166
28	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
29	Care without a compass: Including patients with cancer in COVID-19 studies. <i>Cancer Cell</i> , 2021, 39, 895-896.	7.7	14
30	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
31	A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. <i>Targeted Oncology</i> , 2021, 16, 633-642.	1.7	8
32	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 155, 291-293.	1.3	19
33	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	3.4	42
34	PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation. <i>Cell Reports</i> , 2021, 36, 109747.	2.9	9
35	Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. , 2021, 9, e003281.		9
36	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 468.e1-468.e5.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e306-e312.	0.9	12
38	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. <i>Biomarker Research</i> , 2021, 9, 80.	2.8	16
39	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	3.2	25
40	906â€¦Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme. , 2021, 9, A951-A951.		0
41	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.	2.8	32
42	Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 662723.	1.3	11
43	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, , .	0.9	9
44	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 891-905.	0.5	0
45	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 793-803.	3.2	117
46	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	0.9	52
47	Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 429-435.	0.9	45
48	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	7.7	219
49	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	5.1	160
50	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	5.1	466
51	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
52	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020, 15, 477-483.	1.7	4
53	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	2.0	343
54	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108

#	ARTICLE	IF	CITATIONS
55	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	4.1	229
56	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	2.0	18
57	To Treat or Not to Treat—Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1868.	3.4	6
58	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2662.	1.7	31
59	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	0.9	20
60	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020, 123, 1590-1598.	2.9	57
61	Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports. <i>Frontiers in Oncology</i> , 2020, 10, 609235.	1.3	9
62	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
63	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262
64	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.	1.1	4
65	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
66	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
67	MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma. <i>Molecular Metabolism</i> , 2020, 34, 136-145.	3.0	18
68	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 211-220.	1.7	14
69	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	2.9	36
70	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.	0.6	12
71	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. <i>JCO Global Oncology</i> , 2020, 6, 293-306.	0.8	4
72	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020, 84, 101966.	3.4	44

#	ARTICLE	IF	CITATIONS
73	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 500-508.	0.9	10
74	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. <i>Cancer Cell</i> , 2020, 37, 738-741.	7.7	46
75	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.	0.9	44
76	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
77	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
78	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. <i>Clinical Cancer Research</i> , 2020, 26, 2087-2095.	3.2	35
79	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	7.7	196
80	Pancreatic tropism of metastatic renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	2.3	55
81	Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101. <i>Journal of Clinical Oncology</i> , 2020, 38, 5061-5061.	0.8	6
82	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC). <i>Journal of Clinical Oncology</i> , 2020, 38, 5062-5062.	0.8	3
83	Phase III study of the hypoxia-inducible factor 2Î± (HIF-2Î±) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5094-TPS5094.	0.8	8
84	Gender impact on renal cell carcinoma survival: A population-based analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, e17099-e17099.	0.8	0
85	Data to decisions: The impact of online education on immunotherapy in advanced renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, e17076-e17076.	0.8	0
86	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	5.1	594
87	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1386-1394.	5.1	69
88	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514.	2.6	50
89	HIF Inhibitors: Status of Current Clinical Development. <i>Current Oncology Reports</i> , 2019, 21, 6.	1.8	230
90	Adjuvant therapy in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 2935-2944.	2.0	47

#	ARTICLE	IF	CITATIONS
91	Immunotherapy for renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 897-905.	1.4	14
92	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 393, 2404-2415.	6.3	778
93	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. , 2019, 7, 127.		23
94	A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. <i>Cancer</i> , 2019, 125, 2400-2408.	2.0	18
95	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	13.9	1,824
96	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	13.9	2,319
97	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 177-182.	0.9	11
98	Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs. <i>Cancer Immunology Research</i> , 2019, 7, 1687-1699.	1.6	33
99	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
100	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 65-71.	0.9	9
101	Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 411.	3.4	63
102	Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. <i>BMC Cancer</i> , 2019, 19, 17.	1.1	4
103	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 297-310.	5.1	207
104	Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens. <i>American Journal of Clinical Pathology</i> , 2019, 151, 217-225.	0.4	25
105	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. <i>Oncologist</i> , 2019, 24, 4-8.	1.9	7
106	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	3.2	48
107	Radical shifts in the first-line management of metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 71-72.	12.5	4
108	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e505-e512.	0.9	24



#	ARTICLE	IF	CITATIONS
109	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. Journal of Clinical Oncology, 2019, 37, 4500-4500.	0.8	85
110	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. Journal of Clinical Oncology, 2019, 37, 4513-4513.	0.8	61
111	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncology, The, 2018, 19, 451-460.	5.1	228
112	Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes. Clinical Cancer Research, 2018, 24, 2979-2980.	3.2	6
113	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	3.2	7
114	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Targeted Oncology, 2018, 13, 353-361.	1.7	14
115	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 405-412.	0.8	40
116	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clinical Genitourinary Cancer, 2018, 16, e879-e892.	0.9	25
117	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. Clinical Genitourinary Cancer, 2018, 16, e663-e667.	0.9	12
118	Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 2018, 14, 861-875.	1.1	15
119	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clinical Genitourinary Cancer, 2018, 16, 298-304.	0.9	41
120	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e751-e760.	0.9	17
121	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
122	Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis. Clinical Genitourinary Cancer, 2018, 16, e289-e295.	0.9	10
123	Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map Analysis. Urology Practice, 2018, 5, 383-390.	0.2	3
124	Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation. Urology, 2018, 113, e1-e2.	0.5	1
125	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e437-e442.	0.9	23
126	Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy. Clinical Genitourinary Cancer, 2018, 16, e1077-e1082.	0.9	11



#	ARTICLE	IF	CITATIONS
127	Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 31-37.	0.8	49
128	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 $\alpha$ Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 867-874.	0.8	290
129	Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3639-3644.	0.8	9
130	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	1.7	22
131	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018, 124, 3677-3683.	2.0	53
132	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
133	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1237-e1242.	0.9	34
134	Information Transparency in the Drug Approval Process. <i>JAMA Oncology</i> , 2018, 4, 1621.	3.4	1
135	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	2.9	39
136	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , 2018, 24, 4407-4415.	3.2	50
137	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
138	Important Group Differences on the Functional Assessment of Cancer Therapyâ€œKidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2018, 21, 1413-1418.	0.1	7
139	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. <i>Kidney Cancer</i> , 2018, 2, 31-36.	0.2	10
140	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 413-419.e1.	0.9	21
141	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
142	Treatment selection for men with metastatic prostate cancer who progress on upfront chemoâ€œhormonal therapy. <i>Prostate</i> , 2018, 78, 1035-1041.	1.2	11
143	HSD3B1(1245A&gt;C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 3333-3340.	3.9	43
144	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	0.8	12

#	ARTICLE	IF	CITATIONS
145	Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more. <i>Oncotarget</i> , 2018, 9, 14036-14037.	0.8	1
146	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017, 71, 204-209.	0.9	65
147	A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1764-1769.	0.8	36
148	Specific immunotherapy in renal cancer: a systematic review. <i>Therapeutic Advances in Urology</i> , 2017, 9, 45-58.	0.9	5
149	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2.	0.9	14
150	Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. <i>Cancer Science</i> , 2017, 108, 1231-1239.	1.7	21
151	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 333-340.	1.7	5
152	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3557-3565.	3.2	19
153	On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 97-99.	1.1	3
154	Future Challenges for Drug Development in Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 577-579.	0.8	6
155	Treatment of renal cell carcinoma: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 507-524.	157.7	583
156	Emerging immunotherapy in advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 687-693.	0.8	14
157	Imaging strategy and outcome following partial nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 660.e1-660.e8.	0.8	8
158	HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. <i>Nature Communications</i> , 2017, 8, 1769.	5.8	303
159	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>European Urology</i> , 2017, 71, 970-978.	0.9	12
160	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 $\beta$ , IL8, CXCL5, and Mip-1 $\alpha$ . <i>Clinical Cancer Research</i> , 2017, 23, 2346-2355.	3.2	148
161	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e275-e280.	0.9	19
162	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017, 1, 41-47.	0.2	13

#	ARTICLE	IF	CITATIONS
163	Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 57-63.	0.2	39
164	Management of the small renal mass. <i>Translational Andrology and Urology</i> , 2017, 6, 923-930.	0.6	32
165	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3851-3858.	0.8	384
166	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	0.8	316
167	Comparative Effectiveness of Tumor Response Assessment Methods: Standard of Care Versus Computer-Assisted Response Evaluation. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-16.	1.0	3
168	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	0.8	6
169	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 113-117.	1.8	11
170	Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1224-1231.	2.1	54
171	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 499-503.	0.9	39
172	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	3.4	154
173	Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. <i>International Urology and Nephrology</i> , 2016, 48, 1253-1260.	0.6	12
174	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 577-584.	1.1	12
175	Emerging therapeutics in refractory renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1225-1232.	0.9	15
176	Changing Landscape of Refractory Renal Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 422-423.	2.5	0
177	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	0.8	174
178	Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?. <i>Clinical Cancer Research</i> , 2016, 22, 5626-5628.	3.2	6
179	Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1031-1041.	0.6	20
180	Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 948-958.	1.6	26

#	ARTICLE	IF	CITATIONS
181	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1599-1611.	5.1	181
182	Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1317-1324.	5.1	200
183	MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. <i>British Journal of Cancer</i> , 2016, 115, 920-928.	2.9	43
184	Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. <i>Journal of Neurosurgery: Spine</i> , 2016, 25, 766-774.	0.9	51
185	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269.	1.6	29
186	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	5.1	789
187	Axitinib for the treatment of metastatic renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 303-311.	1.1	6
188	Prospective Clinical Study of Precision Oncology in Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	70
189	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	3.2	193
190	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.	0.9	133
191	Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668.	0.8	99
192	Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. <i>Targeted Oncology</i> , 2016, 11, 229-234.	1.7	17
193	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 345-351.	0.9	53
194	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 113-117.	1.8	7
195	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015, 2, 1814-1820.	2.7	13
196	Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-4.	0.2	2
197	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. <i>Journal of Urology</i> , 2015, 194, 297-303.	0.2	80
198	Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 212.	3.4	9

#	ARTICLE	IF	CITATIONS
199	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685.	5.1	229
200	Relapse models for clear cell renal carcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e378.	5.1	0
201	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	0.9	78
202	Toward individualized treatment in urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 170.	0.8	0
203	Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 112.e15-112.e21.	0.8	60
204	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2015, 16, 293-300.	5.1	299
205	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	0.9	75
206	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	13.9	1,004
207	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	2.9	88
208	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma – Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	1.9	23
209	Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 540-547.e7.	0.9	22
210	Emerging therapeutic approaches in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1305-1314.	1.1	16
211	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.	0.9	41
212	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.	0.9	10
213	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	0.8	19
214	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	0.8	914
215	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. <i>European Urology</i> , 2015, 67, 85-97.	0.9	403
216	Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Pharmacokinetics</i> , 2015, 54, 397-407.	1.6	12

#	ARTICLE	IF	CITATIONS
217	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , 2015, 10, 45-53.	1.7	45
218	The use of sunitinib in renal cell carcinoma: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 983-999.	1.1	7
219	Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014, 120, 52-60.	2.0	40
220	Surgical Outcomes After Cyto-reductive Nephrectomy With Inferior Vena Cava Thrombectomy. <i>Urology</i> , 2014, 84, 1414-1419.	0.5	30
221	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358.	0.9	26
222	The ineligible patient: how to treat patients not included in clinical studies. <i>World Journal of Urology</i> , 2014, 32, 9-18.	1.2	9
223	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. <i>European Urology</i> , 2014, 65, 577-584.	0.9	207
224	Randomized Phase III Trial of Temozolomide and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 752-759.	0.8	179
225	Molecular Biomarkers in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 2060-2071.	3.2	62
226	Cyto-reductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.	0.9	382
227	Dual VEGF/VEGFR inhibition in advanced solid malignancies. <i>Cancer Biology and Therapy</i> , 2014, 15, 975-981.	1.5	19
228	Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond. <i>Seminars in Oncology</i> , 2014, 41, 235-251.	0.8	129
229	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 335-340.	0.9	9
230	Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma. <i>European Urology</i> , 2014, 65, 667-668.	0.9	3
231	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.	0.9	69
232	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	0.9	25
233	Computed Tomography Characteristics of Unresectable Primary Renal Cell Carcinoma Treated With Neoadjuvant Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 117-123.	0.9	2
234	Signal Integration and Gene Induction by a Functionally Distinct STAT3 Phosphoform. <i>Molecular and Cellular Biology</i> , 2014, 34, 1800-1811.	1.1	35



#	ARTICLE	IF	CITATIONS
235	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	0.9	71
236	Practice challenges affecting optimal care as identified by US medical oncologists who treat renal cell carcinomas. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 197-204.	0.1	1
237	Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. <i>Cancer</i> , 2013, 119, 313-324.	2.0	43
238	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.	1.7	47
239	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1233-1242.	5.1	215
240	Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1283-1291.	0.8	23
241	Metastatic non-“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	2.0	189
242	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 311-315.	0.9	64
243	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology</i> , The, 2013, 14, 141-148.	5.1	808
244	Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 107-114.	0.9	42
245	Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective. <i>Seminars in Oncology</i> , 2013, 40, 419-420.	0.8	2
246	Metabolism of Kidney Cancer: From the Lab to Clinical Practice. <i>European Urology</i> , 2013, 63, 244-251.	0.9	61
247	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 552-562.	5.1	640
248	A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 1044-1050.	1.2	14
249	The Context of Blood Vessels and Response to VEGF-Targeted Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 6647-6649.	3.2	3
250	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. <i>Anti-Cancer Drugs</i> , 2013, 24, 431-440.	0.7	13
251	Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 491-504.	1.0	122
252	Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA349-LBA349.	0.8	8



#	ARTICLE	IF	CITATIONS
253	Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2012, 2, 51.	1.3	18
254	Novel agents in renal carcinoma: a reality check. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 183-194.	1.4	53
255	The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery. <i>Journal of Urology</i> , 2012, 187, 1548-1554.	0.2	79
256	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935.	5.1	112
257	State of the Science: An Update on Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2012, 10, 859-880.	1.5	142
258	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. <i>Cancer</i> , 2012, 118, 1946-1954.	2.0	115
259	Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead. <i>Cancer</i> , 2012, 118, 2583-2593.	2.0	41
260	Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 3277-3282.	2.0	19
261	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney. <i>Cancer</i> , 2012, 118, 6152-6161.	2.0	97
262	Current Treatment Considerations in Metastatic Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 212-229.	1.3	30
263	Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon- $\gamma$ in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2012, 109, 63-69.	1.3	12
264	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. <i>European Urology</i> , 2012, 61, 307-316.	0.9	52
265	p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. <i>Seminars in Oncology</i> , 2012, 39, 97-108.	0.8	51
266	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , 2012, 118, 365-370.	2.0	21
267	Determining the optimal dose and schedule of sunitinib. <i>Cancer</i> , 2012, 118, 1178-1180.	2.0	6
268	A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 364-367.	1.2	14
269	Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 354-354.	0.8	12
270	Vascular Endothelial Growth Factor-Targeted Therapies in Advanced Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 813-833.	0.9	46

#	ARTICLE	IF	CITATIONS
271	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. <i>International Immunopharmacology</i> , 2011, 11, 856-861.	1.7	257
272	Targeted therapy for patients with renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2011, 12, 1085-1087.	5.1	8
273	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1931-1939.	6.3	1,663
274	Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. <i>BJU International</i> , 2011, 107, 562-570.	1.3	18
275	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690.	0.9	125
276	Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. <i>Investigational New Drugs</i> , 2011, 29, 1441-1448.	1.2	13
277	Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining. <i>Journal of Clinical Immunology</i> , 2011, 31, 690-698.	2.0	13
278	Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. <i>Journal of Cancer Survivorship</i> , 2011, 5, 255-262.	1.5	4
279	Germline and somatic DNA methylation and epigenetic regulation of <i>KILLIN</i> in renal cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 654-661.	1.5	33
280	Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2011, 117, 758-767.	2.0	143
281	The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Cancer</i> , 2011, 117, 1183-1189.	2.0	23
282	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011, 117, 2637-2642.	2.0	74
283	Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. <i>International Journal of Cancer</i> , 2011, 129, 2158-2170.	2.3	127
284	Pazopanib for the treatment of renal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1171-1189.	0.9	17
285	Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 763-773.	3.0	526
286	Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3841-3849.	3.2	173
287	Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 591-599.	0.6	295
288	Noncytotoxic Differentiation Treatment of Renal Cell Cancer. <i>Cancer Research</i> , 2011, 71, 1431-1441.	0.4	30

#	ARTICLE	IF	CITATIONS
289	Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 337-8.	0.3	3
290	Renal cell carcinoma: ten years of significant advances. <i>Targeted Oncology</i> , 2010, 5, 73-74.	1.7	4
291	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. <i>Cancer</i> , 2010, 116, 5383-5390.	2.0	63
292	Sunitinib rechallenge in metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 5400-5406.	2.0	123
293	Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , 2010, 106, 1266-1269.	1.3	65
294	Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy. <i>American Journal of Roentgenology</i> , 2010, 194, 1470-1478.	1.0	216
295	New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance. <i>Clinical Cancer Research</i> , 2010, 16, 1348-1354.	3.2	80
296	Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. <i>Cancer Research</i> , 2010, 70, 1063-1071.	0.4	394
297	Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e284-e285.	0.8	43
298	Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. <i>Journal of Clinical Oncology</i> , 2010, 28, 2137-2143.	0.8	746
299	Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained. <i>Cancer Research</i> , 2010, 70, 3526-3536.	0.4	269
300	Editorial Comment. <i>Urology</i> , 2010, 75, 1114-1115.	0.5	0
301	Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. <i>Urology</i> , 2010, 76, 430-434.	0.5	75
302	Biomarkers: hypertension following anti-angiogenesis therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 415-6.	0.3	12
303	Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2009, 2, 51.	1.0	30
304	Elevated Levels of Select Gangliosides in T Cells from Renal Cell Carcinoma Patients Is Associated with T Cell Dysfunction. <i>Journal of Immunology</i> , 2009, 183, 5050-5058.	0.4	48
305	GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells. <i>Cancer Research</i> , 2009, 69, 3095-3104.	0.4	57
306	Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 2148-2157.	3.2	792

#	ARTICLE	IF	CITATIONS
307	Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 235-241.	0.8	214
308	A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 6277-6283.	3.2	84
309	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799.	0.8	1,751
310	Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF. <i>Cancer Research</i> , 2009, 69, 609-615.	0.4	238
311	Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2306-2312.	2.0	84
312	Circulating tumor cells in metastatic castration-resistant prostate cancer. <i>Current Oncology Reports</i> , 2009, 11, 163-164.	1.8	0
313	Integration of surgery and systemic therapy in the management of metastatic renal cancer. <i>Current Urology Reports</i> , 2009, 10, 35-41.	1.0	9
314	The HLA-A*24-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. <i>Prostate</i> , 2009, 69, 142-148.	1.2	10
315	Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient. <i>Journal of Clinical Oncology</i> , 2009, 27, 3225-3234.	0.8	105
316	Editorial Comment. <i>Journal of Urology</i> , 2009, 182, 2599-2600.	0.2	3
317	Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4462-4468.	0.8	323
318	Resistance to targeted therapy in renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2009, 10, 992-1000.	5.1	496
319	Renal cell carcinoma. <i>Lancet</i> , The, 2009, 373, 1119-1132.	6.3	1,363
320	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity. <i>American Journal of Surgical Pathology</i> , 2009, 33, 72-80.	2.1	84
321	Renal Angiomyolipoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 289-297.	2.1	216
322	Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 1309-1314.	2.0	42
323	Axitinib for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 741-748.	1.9	60
324	Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 79-85.	0.9	10

#	ARTICLE	IF	CITATIONS
325	Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 895-905.	1.1	7
326	Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 543-549.	0.8	64
327	Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 6674-6682.	3.2	444
328	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3743-3748.	0.8	381
329	Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. <i>Journal of Clinical Oncology</i> , 2008, 26, 5422-5428.	0.8	874
330	Lapatinib therapy for patients with advanced renal cell carcinoma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 626-627.	4.3	1
331	GM1 and Tumor Necrosis Factor- $\alpha$ , Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis. <i>Cancer Research</i> , 2008, 68, 2014-2023.	0.4	38
332	Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin. <i>Clinical Cancer Research</i> , 2008, 14, 1286-1290.	3.2	156
333	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 127-131.	0.8	373
334	Is sorafenib plus interferon $\beta$ safe and effective in patients with renal cell carcinoma?. <i>Nature Reviews Urology</i> , 2008, 5, 132-133.	1.4	7
335	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2008, 20, 300-306.	1.1	120
336	Targeted therapy in renal cell carcinoma. <i>Current Opinion in Urology</i> , 2008, 18, 481-487.	0.9	14
337	PD2-3 Towards Optimal Management of Metastatic Renal Cell Carcinoma : an Update on the Role of Sunitinib as First-line Treatment. <i>Japanese Journal of Urology</i> , 2008, 99, 133.	0.0	0
338	Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?. <i>Oncology</i> , 2008, 22, 388-96; discussion 396, 402-3, 476 passim.	0.4	10
339	A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1810-1815.	3.2	385
340	Sunitinib. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2359-2369.	0.9	66
341	Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 741s-746s.	3.2	36
342	Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions. <i>Clinical Cancer Research</i> , 2007, 13, 1098-1106.	3.2	161

#	ARTICLE	IF	CITATIONS
343	Response: Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 976-977.	3.0	7
344	Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference: Fig. 1.. <i>Clinical Cancer Research</i> , 2007, 13, 667s-670s.	3.2	36
345	Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 81-83.	3.0	370
346	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2007, 19, 234-240.	1.1	13
347	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. <i>Lancet Oncology</i> , The, 2007, 8, 975-984.	5.1	428
348	The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy. <i>Journal of Urology</i> , 2007, 177, 1978-1984.	0.2	81
349	Sorafenib in Advanced Renal Cancer. <i>Drugs</i> , 2007, 67, 484-485.	4.9	0
350	The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Scientific World Journal</i> , The, 2007, 7, 800-807.	0.8	4
351	Temsirolimus. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 599-600.	21.5	40
352	Immunotherapy for metastatic renal cell carcinoma. <i>BJU International</i> , 2007, 99, 1282-1288.	1.3	22
353	Recent Progress in the Management of Advanced Renal Cell Carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 112-125.	157.7	147
354	What Is Standard Initials Systemic Therapy in Metastatic Renal Cell Carcinoma?. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 256-263.	0.9	2
355	The Prognostic Significance of Epidermal Growth Factor Receptor Expression in Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 264-270.	0.9	26
356	A Phase I Trial of Docetaxel/Estramustine/Imatinib in Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 323-328.	0.9	27
357	Prolonged Complete Responses and Near-Complete Responses to Sunitinib in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 446-451.	0.9	30
358	The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics. <i>Targeted Oncology</i> , 2007, 2, 225-234.	1.7	4
359	Sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 453-461.	0.9	86
360	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 16-24.	0.8	1,590

#	ARTICLE	IF	CITATIONS
361	Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 778-785.	2.0	40
362	Current status and future directions of molecular markers in renal cell carcinoma. <i>Current Opinion in Urology</i> , 2006, 16, 332-336.	0.9	16
363	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2006, 18, 289-296.	1.1	32
364	Clinical trials in patients with biochemically relapsed prostate cancer. <i>BJU International</i> , 2006, 97, 905-910.	1.3	2
365	Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. <i>BJU International</i> , 2006, 98, 756-762.	1.3	104
366	A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. <i>BJU International</i> , 2006, 98, 763-769.	1.3	54
367	VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices. <i>Current Oncology Reports</i> , 2006, 8, 85-89.	1.8	11
368	The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2006, 33, 596-606.	0.8	34
369	Clinical Activity of Sorafenib and Sunitinib in Renal Cell Carcinoma Refractory to Previous Vascular Endothelial Growth Factor-Targeted Therapy: Two Case Reports. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 78-81.	0.9	16
370	Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 110-113.	0.9	16
371	Patients with Metastatic Renal Cell Carcinoma with Long-Term Disease-Free Survival After Treatment with Sunitinib and Resection of Residual Metastases. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 232-234.	0.9	38
372	Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 106, 566-575.	2.0	56
373	Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. <i>Cancer</i> , 2006, 107, 67-74.	2.0	119
374	A phase II study of gemcitabine and capecitabine in metastatic renal cancer. <i>Cancer</i> , 2006, 107, 1273-1279.	2.0	68
375	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.	3.8	1,111
376	Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2006, 20, 504-508.	1.1	33
377	Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 602-603.	4.3	9
378	Molecularly targeted therapy in renal cell carcinoma: where do we go from here?. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1753-1760.	1.1	2



#	ARTICLE	IF	CITATIONS
379	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2005, 17, 261-267.	1.1	11
380	Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. <i>BJU International</i> , 2005, 96, 286-290.	1.3	51
381	A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. <i>Cancer</i> , 2005, 103, 553-558.	2.0	19
382	VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2005, 10, 191-197.	1.9	58
383	What are the prognostic factors for survival in patients with metastatic renal cell carcinoma?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 292-293.	4.3	1
384	Molecularly targeted therapy in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1031-1040.	1.1	33
385	Antigen-Presenting Cells 8015 (Provenge®) in Patients with Androgen-Dependent, Biochemically Relapsed Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2005, 4, 55-60.	2.1	55
386	SU11248 and AG013736: Current Data and Future Trials in Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2005, 4, 175-180.	0.9	16
387	Cancer and Leukemia Group B 90206. <i>Clinical Cancer Research</i> , 2004, 10, 2584-2586.	3.2	158
388	Recent clinical development of dendritic cell-based immunotherapy for prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1729-1734.	1.4	6
389	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. <i>Blood</i> , 2004, 104, 810-810.	0.6	5
390	Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 99-105.	0.8	87
391	Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results. <i>Journal of Clinical Oncology</i> , 2002, 20, 2017-2024.	0.8	169
392	Prostate cancer update. <i>Current Opinion in Oncology</i> , 2002, 14, 286-291.	1.1	23
393	A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2002, 95, 1629-1636.	2.0	119
394	Hormone-Refractory prostate cancer. <i>Current Treatment Options in Oncology</i> , 2002, 3, 437-446.	1.3	21
395	Technology evaluation: APC-8015, Dendreon. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 76-9.	2.8	26
396	An update on prostate cancer. <i>Current Opinion in Oncology</i> , 2001, 13, 204-211.	1.1	12

#	ARTICLE	IF	CITATIONS
397	Isolated, Primary Extranodal Hodgkin's Disease of the Spine: Case Report. Neurosurgery, 2001, 49, 453-457.	0.6	36
398	Immunotherapy for prostate cancer. Current Oncology Reports, 2001, 3, 418-423.	1.8	9
399	Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology, 2000, 18, 2419-2426.	0.8	154
400	Reply to S. Tan et al. Journal of Clinical Oncology, 0, , .	0.8	0